Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy

Human epidermal growth factor receptor 2 (HER2)–positive breast cancers are currently treated with trastuzumab, an anti-HER2 antibody. About 30% of these tumors express a group of HER2 fragments collectively known as p95HER2. Our previous work indicated that p95HER2-positive tumors are resistant to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Natl Cancer Inst
Autors principals: Parra-Palau, Josep Lluís, Morancho, Beatriz, Peg, Vicente, Escorihuela, Marta, Scaltriti, Maurizio, Vicario, Rocio, Zacarias-Fluck, Mariano, Pedersen, Kim, Pandiella, Atanasio, Nuciforo, Paolo, Serra, Violeta, Cortés, Javier, Baselga, José, Perou, Charles M., Prat, Aleix, Rubio, Isabel T., Arribas, Joaquín
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2014
Matèries:
Brief Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4271027/
https://ncbi.nlm.nih.gov/pubmed/25253614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/dju291
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars